Correspondence 0001193125-26-187838 from Rein Therapeutics, Inc. (RNTX)
Rein Therapeutics, Inc.
Date: April 28, 2026 · CIK: 0001420565 · Accession: 0001193125-26-187838
AI Filing Summary & Sentiment
Reasoning
Letter
Re:
April 28, 2026 VIA EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549
Attn:
Jimmy McNamara
Rein Therapeutics, Inc.
Registration Statement on Form S-1
CIK 0001420565
Acceleration Request
Requested Date:
Thursday, April 30, 2026
Requested Time:
5:00 p.m., Eastern Daylight Time Ladies and Gentlemen: In accordance with Rule 461 under the Securities Act of 1933, as amended, the undersigned registrant, Rein Therapeutics, Inc. (the “ Registrant ”), hereby requests that the Securities and Exchange Commission (the “ Commission ”) take appropriate action to cause the Registration Statement on Form S-1 publicly filed with the Commission on April 28, 2026 (the “ Registration Statement ”) to become effective on April 30, 2026, at 5:00 p.m., Eastern Daylight Time, or as soon as practicable thereafter, or at such later time as the Registrant may orally request via telephone call to the staff of the Commission (the “ Staff ”). The Registrant hereby authorizes Daniel Donahue of Greenberg Traurig, LLP, counsel to the Registrant, to make such request on its behalf. Once the Registration Statement has been declared effective, please orally confirm that event with Mr. Donahue at (949) 732-6557. In connection with this request, the Registrant acknowledges that:
•
should the Commission or the Staff, acting pursuant to delegated authority, declare the Registration Statement effective, it does not foreclose the Commission from taking any action with respect to the Registration Statement;
•
the action of the Commission or the Staff, acting pursuant to delegated authority, in declaring the Registration Statement effective, does not relieve the Registrant from its full responsibility for the adequacy and accuracy of the disclosure in the Registration Statement; and
•
the Registrant may not assert Staff comments and the declaration of effectiveness as a defense in any proceeding initiated by the Commission or any person under the federal securities laws of the United States.
Very truly yours,
Rein Therapeutics, Inc.
Show Raw Text
CORRESP 1 filename1.htm CORRESP April 28, 2026 VIA EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Attn: Jimmy McNamara Re: Rein Therapeutics, Inc. Registration Statement on Form S-1 CIK 0001420565 Acceleration Request Requested Date: Thursday, April 30, 2026 Requested Time: 5:00 p.m., Eastern Daylight Time Ladies and Gentlemen: In accordance with Rule 461 under the Securities Act of 1933, as amended, the undersigned registrant, Rein Therapeutics, Inc. (the “ Registrant ”), hereby requests that the Securities and Exchange Commission (the “ Commission ”) take appropriate action to cause the Registration Statement on Form S-1 publicly filed with the Commission on April 28, 2026 (the “ Registration Statement ”) to become effective on April 30, 2026, at 5:00 p.m., Eastern Daylight Time, or as soon as practicable thereafter, or at such later time as the Registrant may orally request via telephone call to the staff of the Commission (the “ Staff ”). The Registrant hereby authorizes Daniel Donahue of Greenberg Traurig, LLP, counsel to the Registrant, to make such request on its behalf. Once the Registration Statement has been declared effective, please orally confirm that event with Mr. Donahue at (949) 732-6557. In connection with this request, the Registrant acknowledges that: • should the Commission or the Staff, acting pursuant to delegated authority, declare the Registration Statement effective, it does not foreclose the Commission from taking any action with respect to the Registration Statement; • the action of the Commission or the Staff, acting pursuant to delegated authority, in declaring the Registration Statement effective, does not relieve the Registrant from its full responsibility for the adequacy and accuracy of the disclosure in the Registration Statement; and • the Registrant may not assert Staff comments and the declaration of effectiveness as a defense in any proceeding initiated by the Commission or any person under the federal securities laws of the United States. Very truly yours, Rein Therapeutics, Inc. By: /s/ Brian Windsor Brian Windsor, Ph.D., President and Chief Executive Officer cc: Daniel Donahue, Greenberg Traurig, LLP